SEC Form 4 · accession 0001193125-26-274534
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Zalevsky
Officer — Chief R&D Officer
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 7:12 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 15, 2026 | S | 5,538 | $60.71 | D | 15,437 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
- F2This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.